SARomics Biostructures Brings in New Strategic Owners
News Sep 15, 2012
SARomics Biostructures AB has announced that Innovationsbron AB and Lund University Innovation System AB (LUIS AB) are investing in and becoming new co-owners of the company alongside the founders.
The new investment will allow the company to expand its primary business of generating 3D structural information of proteins and protein-ligand complexes.
SARomics Biostructures is a major user of MAX-lab, the Swedish national synchrotron facility in Lund, and aims to position itself as a leading European structural biology service provider when the new world-class MAX IV synchrotron opens in 2015.
Linus Wiebe, CEO of LUIS said “SARomics Biostructures has shown the commercial potential of MAX-lab and we believe that our strategic investment will leverage the company to take full advantage of MAX IV in the future.”
SARomics Biostructures gene-to-structure platform has successfully been applied to determine structures of many important drug targets, biopharmaceuticals, and industrial enzymes for partners from both the life science industry and academia worldwide.
The company is currently expanding its off-the-shelf portfolio of “ready made” crystal structures of important drug targets and will also engage in internal lead discovery programs.
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018